Last reviewed · How we verify
A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133) (TANGO)
This study will evaluate the efficacy, tolerability, and effect on the quality of life of infliximab in adults with moderate-to-severe psoriasis who are resistant to etanercept after 12 weeks of treatment or have failed 24 weeks of treatment with etanercept. Infliximab will be administered as an intravenous infusion of 5 mg/kg at Baseline (Week 0), Visit 3 (Week 2), Visit 4 (Week 6), Visit 6 (Week 14), and Visit 8 (Week 22).
Details
| Lead sponsor | Merck Sharp & Dohme LLC |
|---|---|
| Phase | PHASE4 |
| Status | COMPLETED |
| Enrolment | 48 |
| Start date | Mon Oct 01 2007 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Oct 01 2009 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Psoriasis
Interventions
- Infliximab